Genfarma - Technology Transfer Platform Connecting Global Biotechnology with Vietnam’s Healthcare

Genfarma - Technology Transfer Platform
Connecting Global Biotechnology with Vietnam’s Healthcare

In the global biopharmaceutical industry, Technology Transfer (TT) is the most critical and technically demanding discipline: it requires absorbing advanced scientific know-how from international originators (Sending Un its - SUs) and reproducing it locally with absolute molecular equivalence, purity, biological potency, and sterility assurance.

In Vietnam, WE – GENFARMA, Receiving Unit (RU) possess the cleanroom infrastructure, analytical rigor, risk governance, and multidisciplinary human capital required to connect global biotechnology innovation with domestic cGMP manufacturing excellence - delivering internationally compliant, life-saving biotherapeutics to hospitals and patients across Vietnam.

Global Sending Unit (SU)

INTERNACIONAL TECHNOLOGY LICENSORS

Receiving Unit (RU) – Vietnam

GENFARMA – HIGH-TECH BIOLOGICS HUB

Hospitals & Benefitting Patients

DIRECT CLINICAL BENEFICIARIES IN VIETNAM

 

 

I.            Vaccine & Biologic Transfer Readiness

§  Existing manufacturing foundation: solution preparation, vial filling, lyophilization and packaging, supported by QC and temperature-controlled storage

§  Vaccine transfer opportunities: evaluate local fill & finish of selected partner vaccine bulks in compatible vial formats

§  Biologic transfer opportunities: evaluate formulation and fill & finish of compatible liquid or lyophilized products

§  Product-specific assessment: confirm containment, formulation compatibility, analytical methods, cold-chain requirements and stability

§  Commercial readiness: define facility adaptations, qualification, process validation and regulatory approvals with each technology partner

 II.         Master Portfolio Executive Dashboard

Projects are managed according to an implementation model that includes product-specific GAP and feasibility assessment; agreed transfer scope & applicable regulatory approvals; readiness preparation; execution of Process Performance Qualification (PPQ); and handover to commercial production.

Genfarma concurrently executes 27 complex biopharmaceutical transfer projects and look forward for further collaboration with more SUs worldwide to further contributing for a better Vietnam’s healthcare.
 

Genfarma Live Technology Transfer Pipeline:

 

Total: 27

Active: 26 (96.3%)

Completed: 01 (3.7%)

On Hold: 0 (0%)

Interactive Live Technology Transfer Pipeline:

 

07

mAbs

11

Recombinant Proteins

 

04

Peptides

 

05

Polysaccharides

             

Grounded in PDA Technical Report No. 65 (Technology Transfer) and WHO guidelines, Genfarma Technology transfer is governed as a rigorous 6-Stage lifecycle controlled by formal Go/No-Go quality gates.  

Lifecycle Stage

Title

Technical Objective

Decision Gate

Live Project Count

STAGE 01

1. Initiation (RU)

Technical feasibility & RU site readiness evaluation

Gate 1 (Go / No-Go)

23 Active (85.2%)

STAGE 02

2. Planning (RU)

Master project plan, risk matrix & TT Protocol approval

Gate 2 (Go / No-Go)

0 Active (0%)

STAGE 03

3. Knowledge Transfer

SU-to-RU dossier handover, CPPs/CQAs & technical training

Gate 3 (Go / No-Go)

0 Active (0%)

STAGE 04

4. Readiness (RU)

Cleanroom qualification, analytical transfer & pre-PPQ readiness.

Gate 4 (Go / No-Go)

02 Active (7.4%)

STAGE 05

5. Execution (PPQ)

Commercial-scale PPQ validation batches & comparability.

Gate 5 (Go / No-Go)

01 Active (3.7%)

STAGE 06

6. Handover (RU)

Routine cGMP commercial manufacturing & national supply.

Milestone / Release

01 Completed (3.7%)

Product

Therapeutic Effect & Mechanism

Benefiting Clinical Area

Nimotuzumab - Humanized Monoclonal Antibody

(anti-EGFR mAb)

Selectively binds to the human epidermal growth factor receptor (EGFR) with intermediate affinity, inhibiting tumor cell proliferation and angiogenesis with a benign cutaneous safety profile.

Oncology (Advanced head & neck squamous cell carcinoma, high-grade adult and pediatric astrocytoma / glioma, esophageal cancer)


III.Strategic Governance Pillars for Multi-Product Biopharmaceutical Complexity

Genfarma has developed capabilities and competitive strengths in receiving, developing, and implementing advanced biotechnology and biopharmaceutical projects under full cGMP compliance.


4   
Integrated Pillar

1-      Quality Risk Management & Analysis

Science-based biological risk control across every critical process parameter

Ø ICH Q9(R1) Governance

Ø Robust Supplier Qualification

Ø FMEA & CPP Control

Ø Lifecycle Risk Verification

2-      Facility Engineering & Infrastructure

Advanced aseptic fill and finish engineered for zero cross-contamination

Ø Dedicated biologics filling line

Ø Dedicated HVAC Segregation

Ø High production capacity

Ø Validated Clean CIP/SIP Skids

3-      SU & RU Communication & Training Pillars

Direct scientific immersion between global SUs and Genfarma specialists

Ø Bilateral SU-RU Governance

Ø Licensor Facility Immersion

Ø On-site Licensor Shadowing

Ø Collaborative Gate Sign-Offs

4-      Regulatory Harmonization Across Diverse SUs

Unifying multinational CTD dossiers into compliant national & global submissions

Ø Multinational CTD Unification

Ø Pharmacopeial Reconciliation

Ø WHO-GMP to EU-GMP Harmonization

Ø ICH Q5E Comparability

 

Sterile Productive Capacity & Aseptic Filling Suites

Powered by World-Class Fill and Finish Platform & PUPSIT Technology in Segregated cGMP Cleanrooms — Built to Scale Global Biologics in Vietnam

Existing Fill & Finish Platform:



1.    Solution preparation Capacity

                   §  Stainless steel vessels available for both SS vessels and SUS suitable for batch sizes from 20L to 1,000L
                   §  Heating/cooling jackets and magnetic mixing
                   §  Automated controls with audit trails and electronic records

2. Vial filling Capacity

                     §  Integrated vial washing, dehydrogenation, filling and stoppering
                     §  Suitable for vial from 2R ~ 100R
                     §  Product-specific filling parameters require transfer and validation
                     §  Automated controls support audit trails, electronic records/signatures and data integrity
                     §  Source specifications reference 21 CFR Part 11 and GAMP 5 

3. Lyophilization Capacity

                     § 3 lyophilizes with automatic vial loading and unloading
                     § Automated control, monitoring and electronic records
                     § A platform for transfer of product-specific freeze-drying cycles

4. Inspection & Packaging Capacity

                     §  Integrated automatic inspection, vacuum leak testing and labelling

                     §  Cartooning, online checkweighing and case packing

                     §  Automated controls support electronic records and data integrity: Product-specific inspection criteria and packaging formats form part of transfer

Storage & Cold Chain Infrastructure

Approximately 5,000 m³ of storage capacity is provided within designated areas maintained at defined temperature ranges, as appropriate for the controlled storage of packaging materials, excipients, active pharmaceutical ingredients (APIs), and finished products at their respective stages of operation. 




Key Technological Differentiation
Pre-Use Post-Sterilization Integrity Testing (PUPSIT)
EU–GMP Annex 1

STEP 01

In-Situ Steam Sterilization

Automated SIP sterilization of 0.22 µm biofilters and single-use manifolds

STEP 02

Pre-Use Integrity Verification

Closed-barrier bubble-point & diffusive flow test prior to batch contact

STEP 03

Aseptic Product Filtration

Zero-touch sterile transfer into Grade A dosing needles with live ΔP tracking

STEP 04

Post-Use Dual Confirmation

Immediate post-batch integrity re-test confirming 100% membrane integrity

 

IV. Analytical Method Transfer (AMT) & Biopharmaceutical QC Platform

Powered by ICH-Compliant Analytical Method Transfer & 3-Platform Quality Control — Ensuring Molecular Comparability in Every Vial

Three Core Analytical Platforms . 30 Validated Testing Methods 

 

Physicochemical Platform

14 Validated Testing Methods
§ MOLECULAR INTEGRITY
§ PURITY & PHYSICOCHEMICAL CQAs
§ SEC / RP-UHPLC CHROMATOGRAPHY
§ CAPILARY ELECTROPHORESIS
§ CCIT

Microbiological Platform

10 Validated Testing Methods
§ STERILITY ASSURANCE
§ RECOMBINANT ENDOTOXIN CONTROL (RFC)
§ BIOBURDEN & MICROBIAL ID 
§ CONTINUOUS CLEANROOM EM

Biological Activity: InVivo & In Vitro Analytical Platform

6 Validated Testing Methods
§ MECHANISM OF ACTION
§ TARGET BINDING & FUNCTIONAL POTENCY
§ FLOW CYTOMETRY & IN VIVO/IN VITRO BIOASSAYS 
§ CELL BANKING

 

COMING SOON § PLANNED AUTONOMOUS HUB

Autonomous Biological Activity Center:
In Vivo & In Vitro cGMP Testing Hub
Completed technical milestones . 3-phase pathway to 100% national sovereignty



 V.Genfarma Core Technology Transfer Leadership & Expert Team
MULTIDISCIPLINARY BIOPHARMA LEADERSHIP
12 to 38+ years cGMP execution 

 

1.   OPERATION & TECHNICAL DIVISION DIRECTOR
__________________________________________________

MANUEL ENRIQUE MONTANE,

M.Sc. §  38+ YRS EXP

Key Focus: Biopharma Capital Investments

§  Plant Engineering & CQV

§  Blood Derivatives & Vaccine Tech Transfer

 

 

2.   TECHNOLOGY TRANSFER LEAD
__________________________________________________

DAYMARA GONZÁLEZ FUENTES,

M.Sc. §  25+ YRS EXP

Key Focus: Cross-Border Biopharma Tech Transfer

§  ICH Q8/Q9/Q10 Quality by Design

§  CTD Regulatory Dossiers

 

 

3.   PRODUCTION MANAGER
__________________________________________________

SERGIO CATÁ MURGUIDO,

M.Sc §  30+ YRS EXP

Key Focus: Leader in 20+ Internal & External Technology Transfer

§  Expert in Sterile Product Formulation, Filling & Packaging

 

 

 

 

 

4.  QC MANAGER
________________________________________________

VLADIMIR PEÑA SÁNCHEZ,

M.Sc § 25+ YRS EXP

Key Focus: Biological QC Direction

§  Analytical Method Validation

§ Protein UF/DF & E&L Characterization

 

5.   ENGINEERING MANAGER
________________________________________

VŨ QUANG HƯNG,

Eng. § 12+ YRS EXP

Key Focus: GMP Vaccine & Biopharma Plant Engineering
§  URS / P&ID Review
§  Aseptic Lines & Clean Utilities

 

6.   QA MANAGER

____________________________________________________

NGUYEN CHI THANH,

M.Sc. §  28+ YRS EXP

Key Focus: 5 WHO-GMP Plant Certifications

§  Annex 1 QRM Compliance

§  International Tech Transfers